pioglitazone has been researched along with sirolimus in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Abete, C; Dessì, S; Fossarello, M; Galantuomo, MS; Mulas, MF; Peiretti, E | 1 |
| Abete, C; Dessì, S; Fossarello, M; Mulas, C; Norfo, C; Peiretti, E; Putzolu, M | 1 |
| Abete, C; Cannas, MD; Dessì, S; La Colla, P; Laconi, S; Mulas, C; Norfo, C; Orrù, CD; Pani, A; Putzolu, M; Vascellari, S | 1 |
| Aizawa, Y; Hosaka, Y; Kashimura, T; Miida, T; Oda, H; Oda, M; Ozaki, K; Ozawa, T; Takahashi, K; Tsuchida, K | 1 |
| Ahn, CM; Hong, SJ; Kim, EO; Kim, JS; Kim, ST; Kim, TJ; Lee, KM; Lim, DS; Park, JH | 1 |
| Daida, H; Dohi, T; Iesaki, T; Kasai, T; Kubota, N; Miyauchi, K; Ogita, M; Tsuboi, S; Tsuruta, R; Yokoyama, T | 1 |
| Fujimoto, Y; Iwata, Y; Kitahara, H; Kobayashi, Y; Komuro, I | 1 |
| Bell, GI; Chong, AS; Grossman, EJ; Misawa, R; Park, SY; Tao, J; Wang, XJ; Witkowski, P; Yin, H; Zhong, R | 1 |
1 review(s) available for pioglitazone and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for pioglitazone and sirolimus
| Article | Year |
|---|---|
Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Glucose; Cardiovascular Agents; Cell Movement; Cell Proliferation; Cells, Cultured; Chemokine CCL2; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Glycated Hemoglobin; Humans; Hyperplasia; Hypoglycemic Agents; Inflammation Mediators; Insulin; Interleukin-6; Killer Cells, Natural; Lipids; Male; Middle Aged; Myocytes, Smooth Muscle; Pioglitazone; Prospective Studies; Prosthesis Design; Receptors, CCR2; Republic of Korea; Single-Blind Method; Sirolimus; Thiazolidinediones; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2010 |
Effect of pioglitazone on endothelial dysfunction after sirolimus-eluting stent implantation.
Topics: Acetylcholine; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Stenosis; Coronary Vessels; Drug-Eluting Stents; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Male; Multivariate Analysis; Pioglitazone; Prospective Studies; Sirolimus; Thiazolidinediones; Vasodilator Agents | 2011 |
9 other study(ies) available for pioglitazone and sirolimus
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Fibroblasts isolated from human pterygia exhibit altered lipid metabolism characteristics.
Topics: Aged; Case-Control Studies; Cell Proliferation; Cell Separation; Cell Survival; Cells, Cultured; Cholesterol; Conjunctiva; Esters; Everolimus; Female; Fibroblasts; Humans; Lipid Metabolism; Male; Middle Aged; Pioglitazone; Pterygium; Sirolimus; Thiazolidinediones | 2006 |
Modulation of cholesterol homeostasis by antiproliferative drugs in human pterygium fibroblasts.
Topics: Aged; Amides; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caveolin 1; Cell Division; Cells, Cultured; Cholesterol; Cholesterol Esters; Enzyme Inhibitors; Everolimus; Female; Fibroblasts; Homeostasis; Humans; Hypoglycemic Agents; Immunosuppressive Agents; In Vitro Techniques; Male; Middle Aged; Organosilicon Compounds; Pioglitazone; Progesterone; Pterygium; RNA, Messenger; Sirolimus; Sterol O-Acyltransferase; Thiazolidinediones | 2007 |
Antiprion activity of cholesterol esterification modulators: a comparative study using ex vivo sheep fibroblasts and lymphocytes and mouse neuroblastoma cell lines.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cholesterol; Cholesterol Esters; Dose-Response Relationship, Drug; Esterification; Everolimus; Fibroblasts; Genotype; Lymphocytes; Mice; Neuroblastoma; Pioglitazone; Prions; Scrapie; Sheep; Sheep Diseases; Sirolimus; Thiazolidinediones | 2007 |
Improved cardiac function after sirolimus-eluting stent placement in diabetic patients by pioglitazone: combination therapy with statin.
Topics: Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; PPAR gamma; Sirolimus; Stroke Volume; Thiazolidinediones; Treatment Outcome; Ventricular Function, Left | 2009 |
Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Endothelium, Vascular; Hypoglycemic Agents; Inflammation; Pioglitazone; Protective Agents; Sirolimus; Sus scrofa; Tetrazoles; Thiazolidinediones; Treatment Outcome | 2011 |
Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Experimental; Drug Synergism; Female; Gene Expression; Genes, Reporter; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Insulin-Secreting Cells; Luciferases; Luminescent Measurements; Male; Mice; Pioglitazone; Piperidines; Promoter Regions, Genetic; Regeneration; Sirolimus; Streptozocin; Tacrolimus; Thiazolidinediones; Uracil | 2013 |